Andrew Katims, M.D., M.P.H.

Andrew Katims, M.D., M.P.H., is a urologic oncologist who joined NYMC in 2024. He clinically treats all urologic malignancies and is an expert in bladder, prostate, kidney, and testis cancer. His research is focused on urothelial cancer and ranges from understanding the tumor microenvironment and therapeutically altering the immune system to develop novel treatments to developing clinical models that aim to improve quality of life outcomes for patients with bladder cancer.

His research efforts have led to multiple peer-reviewed publications and awards, including the ASCO Young Investigator Award to study a urine-based bio-marker in upper tract urothelial carcinoma and recognition from both the American Urological Association as an early career investigator and the Bladder Cancer Advocacy Network as an up-and-coming bladder cancer researcher. Ultimately, Dr. Katims aims to improve diagnostic and therapeutic options for all patients, particularly those who are underserved with limited access to tertiary medical centers.

Education

• Fellowship, Urologic Oncology, Memorial Sloan Kettering Cancer Center
• Residency, Urology, Icahn School of Medicine at Mount Sinai Hospital
• M.D., The University of Miami Miller School of Medicine
• M.P.H., The University of Miami Miller School of Medicine
• B.A., Environmental Biology, Washington University in St. Louis

Areas of Expertise

• Bladder Cancer
• Kidney Cancer
• Prostate Cancer
• Testis Cancer
• Penile Cancer
• Complex Robotic Surgery

Honors and Awards

• John Quale Travel Fellowship, Bladder Cancer Advocacy Network, 2025
• Early Career Investigator Showcase Award Nominee, American Urological Association, 2025
• ConquerCancer Young Investigator Award, American Society of Clinical Oncology, 2023

Publications

• Lehner K, Li R, Hensley PJ, et. al. "Smoking is Associated with Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer." Urology, (), (2025) . pii: S0090-4295(25)00808-8. doi: 10.1016/j.urology.2025.08.042
• Katims AB, Tin AL, Assel M, et. al. "Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration)." The Journal of urology, (), (2025) 101097JU0000000000004646. doi: 10.1097/JU.0000000000004646
• Yu A, Hensley PJ, Huelster HL, et. al. "Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma." BJU international, 135(6), (2025) 994-999. doi: 10.1111/bju.16655
• Kim K, Alam SM, Kuo F, et. al. "Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma." European urology, 87(3), (2025) 342-354. doi: 10.1016/j.eururo.2024.10.024
• Lenis AT, Ravichandran V, Brown S, et. al. "Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research, 30(17), (2024) 3894-3903. doi: 10.1158/1078-0432.CCR-23-3403
• Lenis AT, Whiting K, Ravichandran V, et. al. "Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer." JCO precision oncology, 8(), (2024) e2300274. doi: 10.1200/PO.23.00274
• Katims AB, Tallman J, Vertosick E, et. al. "Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial." JAMA oncology, 10(4), (2024) 522-525. doi: 10.1001/jamaoncol.2023.6804

View All Publications

Memberships and Affiliations

• American Urological Association
• Society of Urologic Oncologists